The latest update is out from Terns Pharmaceuticals (TERN).
Terns Pharmaceuticals, Inc. has shared promising data from the Phase 1 study of its drug TERN-701, capturing the attention of the stock market. The details, revealed in a press release, could potentially influence the company’s stock as investors react to the progress of this new pharmaceutical development. However, the information provided does not constitute an official filing under securities law and should not be considered part of the company’s legal disclosures.
See more data about TERN stock on TipRanks’ Stock Analysis page.
